참고문헌
- Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006;119(7 Suppl 1):S30-S35. https://doi.org/10.1016/j.amjmed.2006.05.005
- Kim H, Lee H, Park HC, et al. Characteristics of severe hyponatremia in hospitalized patients: a comparison according to the presence of liver disease. Korean J Nephrol 2008;27:678-687.
- Gross P, Reimann D, Henschkowski J, Damian M. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2001;12 Suppl 17:S10-S14.
- Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-S21. https://doi.org/10.1016/j.amjmed.2007.09.001
- Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 2007;167:1998-2005. https://doi.org/10.1001/archinte.167.18.1998
- Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122:857-865. https://doi.org/10.1016/j.amjmed.2009.01.027
- Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin 2008;24:1601-1608. https://doi.org/10.1185/03007990802081675
- Peri A. Clinical review: the use of vaptans in clinical endocrinology. J Clin Endocrinol Metab 2013;98:1321-1332. https://doi.org/10.1210/jc.2012-4082
- Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112. https://doi.org/10.1056/NEJMoa065181
- Nemerovski C, Hutchinson DJ. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Clin Ther 2010;32:1015-1032. https://doi.org/10.1016/j.clinthera.2010.06.015
- Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011;164:725-732. https://doi.org/10.1530/EJE-10-1078
- Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: association between non-responders and chronic kidney disease. Circ J 2013;77:397-404. https://doi.org/10.1253/circj.CJ-12-0971
- Narayen G, Mandal SN. Vasopressin receptor antagonists and their role in clinical medicine. Indian J Endocrinol Metab 2012;16:183-191. https://doi.org/10.4103/2230-8210.93734
- Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-712. https://doi.org/10.1681/ASN.2009080857
- Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454-2460. https://doi.org/10.1161/01.CIR.0000165065.82609.3D
- Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007;297:1319-1331. https://doi.org/10.1001/jama.297.12.1319
- Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-2696. https://doi.org/10.1161/01.CIR.0000070422.41439.04
- Garcha AS, Khanna A. Review of tolvaptan in the treatment of hyponatremia. Clin Med Insights Ther 2011;3:315-325.
- Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000;85:1207-1211. https://doi.org/10.1016/S0002-9149(00)00729-3
- Shoaf SE, Ohzone Y, Ninomiya S, et al. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol 2011;51:761-769. https://doi.org/10.1177/0091270010376193
피인용 문헌
- Update on heart failure management and future directions vol.34, pp.1, 2018, https://doi.org/10.3904/kjim.2018.428